OrbiMed’s MapLight Therapeutics MPLT Stock Holding History

OrbiMed’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-56,000	Closed	-$952K	–	134
2025 Q4	$952K	Buy	+56,000	New	+$938K	0.02%	105

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed's MPLT Position: Q1 2026 in Review

OrbiMed sold out of MapLight Therapeutics (MPLT) in Q1 2026, closing a stake of 56,000 shares — an estimated $952K sold.

OrbiMed first reported a position in MPLT in Q4 2025 and held it in 1 quarter. The position peaked at $952K in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

OrbiMed reported no remaining MapLight Therapeutics position as of Q1 2026 after selling out during the quarter.
OrbiMed sold 56,000 MapLight Therapeutics shares in Q1 2026, an estimated $952K.
OrbiMed first reported a position in MapLight Therapeutics in Q4 2025 and held it in 1 quarter.
OrbiMed's MapLight Therapeutics position peaked at $952K in Q4 2025.
81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.